191 related articles for article (PubMed ID: 37138674)
1. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.
Hountondji L; Ferreira De Matos C; Lebossé F; Quantin X; Lesage C; Palassin P; Rivet V; Faure S; Pageaux GP; Assenat É; Alric L; Zahhaf A; Larrey D; Witkowski Durand Viel P; Riviere B; Janick S; Dalle S; Maria ATJ; Comont T; Meunier L
JHEP Rep; 2023 Jun; 5(6):100719. PubMed ID: 37138674
[TBL] [Abstract][Full Text] [Related]
2. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.
De Martin E; Michot JM; Rosmorduc O; Guettier C; Samuel D
JHEP Rep; 2020 Dec; 2(6):100170. PubMed ID: 33205034
[TBL] [Abstract][Full Text] [Related]
3. Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors.
Parlati L; Sakka M; Retbi A; Bouam S; Hassani L; Meritet JF; Rufat P; Bonnefont-Rousselot D; Batista R; Terris B; Bellanger A; Thabut D; Vozy A; Spano JP; Coriat R; Goldwasser F; Aractingi S; Sogni P; Pol S; Mallet V; ;
JHEP Rep; 2023 Dec; 5(12):100880. PubMed ID: 38074948
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
5. Cholangitis Induced by Immune Checkpoint Inhibitors: Analysis of Pharmacovigilance Data.
Meunier L; Hountondji L; Jantzem H; Faillie JL; Maria A; Palassin P;
Clin Gastroenterol Hepatol; 2023 Dec; ():. PubMed ID: 38110061
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy.
Kawano M; Yano Y; Yamamoto A; Yasutomi E; Inoue Y; Kitadai J; Yoshida R; Matsuura T; Shiomi Y; Ueda Y; Kodama Y
Diagnostics (Basel); 2024 Apr; 14(8):. PubMed ID: 38667461
[TBL] [Abstract][Full Text] [Related]
7. Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study.
Atallah E; Welsh SJ; O'Carrigan B; Oshaughnessy A; Dolapo I; Kerr AS; Kucharczak J; Lee CYC; Crooks C; Hicks A; Chimakurthi CR; Rao A; Franks H; Patel PM; Aithal GP
JHEP Rep; 2023 Oct; 5(10):100851. PubMed ID: 37727807
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
Respir Med Case Rep; 2022; 40():101773. PubMed ID: 36408484
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
Respir Med Case Rep; 2022; 40():101753. PubMed ID: 36217354
[TBL] [Abstract][Full Text] [Related]
10. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors.
Miller ED; Abu-Sbeih H; Styskel B; Nogueras Gonzalez GM; Blechacz B; Naing A; Chalasani N
Am J Gastroenterol; 2020 Feb; 115(2):251-261. PubMed ID: 31789632
[TBL] [Abstract][Full Text] [Related]
12. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.
Pi B; Wang J; Tong Y; Yang Q; Lv F; Yu Y
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e858-e867. PubMed ID: 34482313
[TBL] [Abstract][Full Text] [Related]
13. The relative expression of hepatocellular and cholestatic liver enzymes in adult patients with liver disease.
Iluz-Freundlich D; Zhang M; Uhanova J; Minuk GY
Ann Hepatol; 2020; 19(2):204-208. PubMed ID: 31628070
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients.
Li M; Wong D; Sack JS; Vogel AS; Hodi FS; Fong L; Lai JC; Zucker SD; Grover S
Clin Gastroenterol Hepatol; 2024 Feb; ():. PubMed ID: 38401693
[TBL] [Abstract][Full Text] [Related]
15. Hepatobiliary and Pancreatic Adverse Events.
Zhang HC; Wang LS; Miller E
Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
[TBL] [Abstract][Full Text] [Related]
16. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies.
Ito T; Ishigami M; Yamamoto T; Mizuno K; Yamamoto K; Imai N; Ishizu Y; Honda T; Kawashima H; Yasuda S; Toyoda H; Yokota K; Hase T; Nishio N; Maeda O; Kato M; Hashimoto N; Hibi H; Kodera Y; Sone M; Ando Y; Akiyama M; Shimoyama Y; Fujishiro M
Hepatol Int; 2021 Oct; 15(5):1278-1287. PubMed ID: 34373964
[TBL] [Abstract][Full Text] [Related]
17. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity.
Robles-Diaz M; Garcia-Cortes M; Medina-Caliz I; Gonzalez-Jimenez A; Gonzalez-Grande R; Navarro JM; Castiella A; Zapata EM; Romero-Gomez M; Blanco S; Soriano G; Hidalgo R; Ortega-Torres M; Clavijo E; Bermudez-Ruiz PM; Lucena MI; Andrade RJ; ;
Liver Int; 2015 Nov; 35(11):2474-82. PubMed ID: 25809419
[TBL] [Abstract][Full Text] [Related]
18. Computed tomography findings of hepatobiliary systems in patients with immune checkpoint inhibitor-induced liver injury.
Masuoka S; Hiyama T; Kuno H; Sasaki T; Oda S; Miyasaka Y; Yamaguchi M; Kobayashi T
Abdom Radiol (NY); 2023 Sep; 48(9):3012-3021. PubMed ID: 37294454
[TBL] [Abstract][Full Text] [Related]
19. An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury.
Riveiro-Barciela M; Barreira-Díaz A; Salcedo MT; Callejo-Pérez A; Muñoz-Couselo E; Iranzo P; Ortiz-Velez C; Cedrés S; Díaz-Mejía N; Ruiz-Cobo JC; Morales R; Aguilar-Company J; Zamora E; Oliveira M; Sanz-Martínez MT; Viladomiu L; Martínez-Gallo M; Felip E; Buti M
Aliment Pharmacol Ther; 2024 Apr; 59(7):865-876. PubMed ID: 38327102
[TBL] [Abstract][Full Text] [Related]
20. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
